(Q38114863)

29 August 2017

title

Paediatric pulmonary hypertension and sildenafil: current practice and controversies (English)

1 reference

29 August 2017

main subject

arterial hypertension

0 references

pulmonary hypertension

1 reference

A J Wardle

1

1 reference

29 August 2017

R M R Tulloh

series ordinal

2

1 reference

29 August 2017

publication date

15 June 2013

1 reference

Archives of Disease in Childhood. Education and Practice Edition

29 August 2017

published in

1 reference

29 August 2017

volume

98

1 reference

29 August 2017

issue

4

1 reference

29 August 2017

page(s)

141-147

1 reference

Guidelines for the diagnosis and treatment of pulmonary hypertension.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Updated clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Response to bosentan in children with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Sildenafil for pulmonary hypertension in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Severe pulmonary arterial hypertension in a very premature baby with bronchopulmonary dysplasia: normalization with long-term sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Sildenafil use in congenital diaphragmatic hernia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Sildenafil as a treatment for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FARCHDISCHILD-2013-303981

10.1136/ARCHDISCHILD-2013-303981

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference